We are very pleased to provide an exciting update on our progress on bringing our therapeutic drug “latiglutenase” and our diagnostic disease management tool “CypCel” to market for patients suffering with celiac disease.
ImmunogenX is a clinical-stage company founded by dedicated scientists committed to bettering the lives of celiac disease patients. We are focused on celiac disease therapy, disease management and food safety. We acquired the assets of Alvine Pharmaceuticals in 2016 and are marching ahead with great confidence and enthusiasm and plan to start our final Phase 2 trial for latiglutenase later this year.
(c) What is Celiac Disease and the Gluten-Free Diet? Celiac.com – Articles – Read story here.